New PET tracer could reveal hidden breast cancer activity
NCT ID NCT03083288
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests a radioactive tracer called [18F]FluorThanatrace to see if it can measure PARP-1, a protein linked to breast cancer, using PET scans. Up to 30 people with known or suspected breast cancer will get a scan before surgery or therapy. The goal is to see if the tracer is safe and if it can help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]FluorThanatrace (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a better way to see breast cancer activity and tailor treatments without invasive biopsies.
What could go wrong
This is a very early phase 1 study with only 30 people. The tracer may not reliably show PARP-1 levels, and it is not a treatment itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States